12:00 AM
 | 
Oct 18, 2010
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

VentiRx preclinical data

In a mouse model of ovarian cancer, VTX-2337 reduced tumor growth compared to both Doxil doxorubicin and vehicle-treated controls. VentiRx plans to start...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >